IBDEI0J0 ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,8552,1,4,0)
;;=4^C82.30
;;^UTILITY(U,$J,358.3,8552,2)
;;=^5001491
;;^UTILITY(U,$J,358.3,8553,0)
;;=C82.49^^39^401^77
;;^UTILITY(U,$J,358.3,8553,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8553,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8553,1,4,0)
;;=4^C82.49
;;^UTILITY(U,$J,358.3,8553,2)
;;=^5001510
;;^UTILITY(U,$J,358.3,8554,0)
;;=C82.40^^39^401^78
;;^UTILITY(U,$J,358.3,8554,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8554,1,3,0)
;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
;;^UTILITY(U,$J,358.3,8554,1,4,0)
;;=4^C82.40
;;^UTILITY(U,$J,358.3,8554,2)
;;=^5001501
;;^UTILITY(U,$J,358.3,8555,0)
;;=C82.99^^39^401^79
;;^UTILITY(U,$J,358.3,8555,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8555,1,3,0)
;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
;;^UTILITY(U,$J,358.3,8555,1,4,0)
;;=4^C82.99
;;^UTILITY(U,$J,358.3,8555,2)
;;=^5001550
;;^UTILITY(U,$J,358.3,8556,0)
;;=C82.90^^39^401^80
;;^UTILITY(U,$J,358.3,8556,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8556,1,3,0)
;;=3^Follicular Lymphoma Unspec,Unspec Site
;;^UTILITY(U,$J,358.3,8556,1,4,0)
;;=4^C82.90
;;^UTILITY(U,$J,358.3,8556,2)
;;=^5001541
;;^UTILITY(U,$J,358.3,8557,0)
;;=R59.1^^39^401^65
;;^UTILITY(U,$J,358.3,8557,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8557,1,3,0)
;;=3^Enlarged Lymph Nodes,Generalized
;;^UTILITY(U,$J,358.3,8557,1,4,0)
;;=4^R59.1
;;^UTILITY(U,$J,358.3,8557,2)
;;=^5019530
;;^UTILITY(U,$J,358.3,8558,0)
;;=C91.40^^39^401^84
;;^UTILITY(U,$J,358.3,8558,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8558,1,3,0)
;;=3^Hairy Cell Leukemia,Not in Remission
;;^UTILITY(U,$J,358.3,8558,1,4,0)
;;=4^C91.40
;;^UTILITY(U,$J,358.3,8558,2)
;;=^5001771
;;^UTILITY(U,$J,358.3,8559,0)
;;=C91.42^^39^401^82
;;^UTILITY(U,$J,358.3,8559,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8559,1,3,0)
;;=3^Hairy Cell Leukemia,In Relapse
;;^UTILITY(U,$J,358.3,8559,1,4,0)
;;=4^C91.42
;;^UTILITY(U,$J,358.3,8559,2)
;;=^5001773
;;^UTILITY(U,$J,358.3,8560,0)
;;=C91.41^^39^401^83
;;^UTILITY(U,$J,358.3,8560,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8560,1,3,0)
;;=3^Hairy Cell Leukemia,In Remission
;;^UTILITY(U,$J,358.3,8560,1,4,0)
;;=4^C91.41
;;^UTILITY(U,$J,358.3,8560,2)
;;=^5001772
;;^UTILITY(U,$J,358.3,8561,0)
;;=D57.01^^39^401^85
;;^UTILITY(U,$J,358.3,8561,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8561,1,3,0)
;;=3^Hb-SS Disease w/ Acute Chest Syndrome
;;^UTILITY(U,$J,358.3,8561,1,4,0)
;;=4^D57.01
;;^UTILITY(U,$J,358.3,8561,2)
;;=^5002307
;;^UTILITY(U,$J,358.3,8562,0)
;;=D57.00^^39^401^86
;;^UTILITY(U,$J,358.3,8562,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8562,1,3,0)
;;=3^Hb-SS Disease w/ Crisis,Unspec
;;^UTILITY(U,$J,358.3,8562,1,4,0)
;;=4^D57.00
;;^UTILITY(U,$J,358.3,8562,2)
;;=^5002306
;;^UTILITY(U,$J,358.3,8563,0)
;;=D57.02^^39^401^87
;;^UTILITY(U,$J,358.3,8563,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8563,1,3,0)
;;=3^Hb-SS Disease w/ Splenic Sequestration
;;^UTILITY(U,$J,358.3,8563,1,4,0)
;;=4^D57.02
;;^UTILITY(U,$J,358.3,8563,2)
;;=^5002308
;;^UTILITY(U,$J,358.3,8564,0)
;;=D68.32^^39^401^89
;;^UTILITY(U,$J,358.3,8564,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,8564,1,3,0)
;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
;;^UTILITY(U,$J,358.3,8564,1,4,0)
;;=4^D68.32
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0J0 3770 printed Sep 23, 2025@19:25:36 Page 2
IBDEI0J0 ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,8552,1,4,0)
+2 ;;=4^C82.30
+3 ;;^UTILITY(U,$J,358.3,8552,2)
+4 ;;=^5001491
+5 ;;^UTILITY(U,$J,358.3,8553,0)
+6 ;;=C82.49^^39^401^77
+7 ;;^UTILITY(U,$J,358.3,8553,1,0)
+8 ;;=^358.31IA^4^2
+9 ;;^UTILITY(U,$J,358.3,8553,1,3,0)
+10 ;;=3^Follicular Lymphoma Grade IIIb,Extranodal/Solid Organ Sites
+11 ;;^UTILITY(U,$J,358.3,8553,1,4,0)
+12 ;;=4^C82.49
+13 ;;^UTILITY(U,$J,358.3,8553,2)
+14 ;;=^5001510
+15 ;;^UTILITY(U,$J,358.3,8554,0)
+16 ;;=C82.40^^39^401^78
+17 ;;^UTILITY(U,$J,358.3,8554,1,0)
+18 ;;=^358.31IA^4^2
+19 ;;^UTILITY(U,$J,358.3,8554,1,3,0)
+20 ;;=3^Follicular Lymphoma Grade IIIb,Unspec Site
+21 ;;^UTILITY(U,$J,358.3,8554,1,4,0)
+22 ;;=4^C82.40
+23 ;;^UTILITY(U,$J,358.3,8554,2)
+24 ;;=^5001501
+25 ;;^UTILITY(U,$J,358.3,8555,0)
+26 ;;=C82.99^^39^401^79
+27 ;;^UTILITY(U,$J,358.3,8555,1,0)
+28 ;;=^358.31IA^4^2
+29 ;;^UTILITY(U,$J,358.3,8555,1,3,0)
+30 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
+31 ;;^UTILITY(U,$J,358.3,8555,1,4,0)
+32 ;;=4^C82.99
+33 ;;^UTILITY(U,$J,358.3,8555,2)
+34 ;;=^5001550
+35 ;;^UTILITY(U,$J,358.3,8556,0)
+36 ;;=C82.90^^39^401^80
+37 ;;^UTILITY(U,$J,358.3,8556,1,0)
+38 ;;=^358.31IA^4^2
+39 ;;^UTILITY(U,$J,358.3,8556,1,3,0)
+40 ;;=3^Follicular Lymphoma Unspec,Unspec Site
+41 ;;^UTILITY(U,$J,358.3,8556,1,4,0)
+42 ;;=4^C82.90
+43 ;;^UTILITY(U,$J,358.3,8556,2)
+44 ;;=^5001541
+45 ;;^UTILITY(U,$J,358.3,8557,0)
+46 ;;=R59.1^^39^401^65
+47 ;;^UTILITY(U,$J,358.3,8557,1,0)
+48 ;;=^358.31IA^4^2
+49 ;;^UTILITY(U,$J,358.3,8557,1,3,0)
+50 ;;=3^Enlarged Lymph Nodes,Generalized
+51 ;;^UTILITY(U,$J,358.3,8557,1,4,0)
+52 ;;=4^R59.1
+53 ;;^UTILITY(U,$J,358.3,8557,2)
+54 ;;=^5019530
+55 ;;^UTILITY(U,$J,358.3,8558,0)
+56 ;;=C91.40^^39^401^84
+57 ;;^UTILITY(U,$J,358.3,8558,1,0)
+58 ;;=^358.31IA^4^2
+59 ;;^UTILITY(U,$J,358.3,8558,1,3,0)
+60 ;;=3^Hairy Cell Leukemia,Not in Remission
+61 ;;^UTILITY(U,$J,358.3,8558,1,4,0)
+62 ;;=4^C91.40
+63 ;;^UTILITY(U,$J,358.3,8558,2)
+64 ;;=^5001771
+65 ;;^UTILITY(U,$J,358.3,8559,0)
+66 ;;=C91.42^^39^401^82
+67 ;;^UTILITY(U,$J,358.3,8559,1,0)
+68 ;;=^358.31IA^4^2
+69 ;;^UTILITY(U,$J,358.3,8559,1,3,0)
+70 ;;=3^Hairy Cell Leukemia,In Relapse
+71 ;;^UTILITY(U,$J,358.3,8559,1,4,0)
+72 ;;=4^C91.42
+73 ;;^UTILITY(U,$J,358.3,8559,2)
+74 ;;=^5001773
+75 ;;^UTILITY(U,$J,358.3,8560,0)
+76 ;;=C91.41^^39^401^83
+77 ;;^UTILITY(U,$J,358.3,8560,1,0)
+78 ;;=^358.31IA^4^2
+79 ;;^UTILITY(U,$J,358.3,8560,1,3,0)
+80 ;;=3^Hairy Cell Leukemia,In Remission
+81 ;;^UTILITY(U,$J,358.3,8560,1,4,0)
+82 ;;=4^C91.41
+83 ;;^UTILITY(U,$J,358.3,8560,2)
+84 ;;=^5001772
+85 ;;^UTILITY(U,$J,358.3,8561,0)
+86 ;;=D57.01^^39^401^85
+87 ;;^UTILITY(U,$J,358.3,8561,1,0)
+88 ;;=^358.31IA^4^2
+89 ;;^UTILITY(U,$J,358.3,8561,1,3,0)
+90 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
+91 ;;^UTILITY(U,$J,358.3,8561,1,4,0)
+92 ;;=4^D57.01
+93 ;;^UTILITY(U,$J,358.3,8561,2)
+94 ;;=^5002307
+95 ;;^UTILITY(U,$J,358.3,8562,0)
+96 ;;=D57.00^^39^401^86
+97 ;;^UTILITY(U,$J,358.3,8562,1,0)
+98 ;;=^358.31IA^4^2
+99 ;;^UTILITY(U,$J,358.3,8562,1,3,0)
+100 ;;=3^Hb-SS Disease w/ Crisis,Unspec
+101 ;;^UTILITY(U,$J,358.3,8562,1,4,0)
+102 ;;=4^D57.00
+103 ;;^UTILITY(U,$J,358.3,8562,2)
+104 ;;=^5002306
+105 ;;^UTILITY(U,$J,358.3,8563,0)
+106 ;;=D57.02^^39^401^87
+107 ;;^UTILITY(U,$J,358.3,8563,1,0)
+108 ;;=^358.31IA^4^2
+109 ;;^UTILITY(U,$J,358.3,8563,1,3,0)
+110 ;;=3^Hb-SS Disease w/ Splenic Sequestration
+111 ;;^UTILITY(U,$J,358.3,8563,1,4,0)
+112 ;;=4^D57.02
+113 ;;^UTILITY(U,$J,358.3,8563,2)
+114 ;;=^5002308
+115 ;;^UTILITY(U,$J,358.3,8564,0)
+116 ;;=D68.32^^39^401^89
+117 ;;^UTILITY(U,$J,358.3,8564,1,0)
+118 ;;=^358.31IA^4^2
+119 ;;^UTILITY(U,$J,358.3,8564,1,3,0)
+120 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
+121 ;;^UTILITY(U,$J,358.3,8564,1,4,0)
+122 ;;=4^D68.32
